DE69530701D1 - Verwendung von 2,7,8-Trimethyl-2-( beta-Carboxyethyl )-6-Hydroxy-Chroman (LLU-alpha) - Google Patents

Verwendung von 2,7,8-Trimethyl-2-( beta-Carboxyethyl )-6-Hydroxy-Chroman (LLU-alpha)

Info

Publication number
DE69530701D1
DE69530701D1 DE69530701T DE69530701T DE69530701D1 DE 69530701 D1 DE69530701 D1 DE 69530701D1 DE 69530701 T DE69530701 T DE 69530701T DE 69530701 T DE69530701 T DE 69530701T DE 69530701 D1 DE69530701 D1 DE 69530701D1
Authority
DE
Germany
Prior art keywords
llu
chroman
carboxyethyl
trimethyl
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69530701T
Other languages
English (en)
Inventor
J Wechter
E Murray
Darko Kantoci
H Levine
J Benaksas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Loma Linda University
Original Assignee
Loma Linda University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loma Linda University filed Critical Loma Linda University
Application granted granted Critical
Publication of DE69530701D1 publication Critical patent/DE69530701D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Read Only Memory (AREA)
DE69530701T 1994-08-15 1995-08-15 Verwendung von 2,7,8-Trimethyl-2-( beta-Carboxyethyl )-6-Hydroxy-Chroman (LLU-alpha) Expired - Lifetime DE69530701D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/290,430 US6150402A (en) 1994-08-15 1994-08-15 Natriuretic compounds
PCT/US1995/010411 WO1996005191A1 (en) 1994-08-15 1995-08-15 Natriuretic cyclic compounds

Publications (1)

Publication Number Publication Date
DE69530701D1 true DE69530701D1 (de) 2003-06-12

Family

ID=23115959

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530701T Expired - Lifetime DE69530701D1 (de) 1994-08-15 1995-08-15 Verwendung von 2,7,8-Trimethyl-2-( beta-Carboxyethyl )-6-Hydroxy-Chroman (LLU-alpha)

Country Status (7)

Country Link
US (2) US6150402A (de)
EP (1) EP0792270B1 (de)
JP (2) JPH10506383A (de)
AT (1) ATE239465T1 (de)
AU (1) AU3327795A (de)
DE (1) DE69530701D1 (de)
WO (1) WO1996005191A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120432A (en) 1997-04-23 2000-09-19 Vascular Science Inc. Medical grafting methods and apparatus
JP2002501018A (ja) 1998-01-26 2002-01-15 マイトコー ミトコンドリア関連疾患を処置するためのミトコンドリア保護剤
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
ES2346181T3 (es) * 2000-03-31 2010-10-13 EISAI R&D MANAGEMENT CO., LTD. Uso de gamma-tocotrienol como diuretico.
US7034054B2 (en) * 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US20030144219A1 (en) 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
JP4118623B2 (ja) * 2002-07-23 2008-07-16 松下電器産業株式会社 不揮発性半導体記憶装置
AU2003291012A1 (en) * 2002-11-15 2004-06-15 Galileo Pharmaceuticals, Inc. Chroman derivatives for the reduction of inflammation symptoms
ITTO20030140U1 (it) * 2003-09-16 2005-03-17 Interfila Srl Matita cosmetica
CA2580584C (en) 2003-09-19 2015-07-28 Galileo Pharmaceuticals, Inc. Use of alpha-tocotrienol for treatment of mitochondrial diseases
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
NZ550441A (en) * 2004-05-05 2009-07-31 Hoffmann La Roche Arylsulfonyl benzodioxanes useful for modulating the 5-HT6 receptor, the 5-HT2A receptor or both
GB2433815B (en) * 2004-10-26 2009-02-25 Spansion Llc Non-volatile memory device
ATE448216T1 (de) * 2004-12-21 2009-11-15 Hoffmann La Roche Tetralin- und indanderivate und anwendungen davon
JP4738418B2 (ja) 2004-12-21 2011-08-03 エフ．ホフマン−ラ ロシュ アーゲー クロマン誘導体及びｃｎｓ障害の処置におけるその使用
KR100889185B1 (ko) * 2004-12-21 2009-03-16 에프. 호프만-라 로슈 아게 테트랄린 및 인단 유도체 및 5-ｈｔ 길항제로서의 이의용도
SI1831159T1 (sl) * 2004-12-21 2010-04-30 Hoffmann La Roche Derivati tetralina in indana ter njune uporabe
MX2007007480A (es) * 2004-12-21 2007-07-20 Hoffmann La Roche Derivados de cromano y su uso como ligandos del receptor 5-ht.
EP1871355A1 (de) * 2005-04-22 2008-01-02 Wyeth Neue therapeutische kombinationen zur behandlung oder prävention von depression
MX2007013179A (es) * 2005-04-22 2008-01-16 Wyeth Corp Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina.
RU2007139541A (ru) * 2005-04-22 2009-05-27 Вайет (Us) Производные хромана и хромена и их применение
CA2610152C (en) * 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
SI1933821T1 (sl) * 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev
RU2008115032A (ru) * 2005-11-03 2009-12-10 Ф. Хоффманн-Ля Рош Аг (Ch) Арилсульфонилхроманы в качестве ингибиторов 5-нт6
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
AU2007233123A1 (en) * 2006-03-30 2007-10-11 Palatin Technologies, Inc. Linear natriuretic peptide constructs
DK2001518T3 (da) * 2006-03-30 2013-10-07 Palatin Technologies Inc Cykliske natriuretiske peptidfremstillinger
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
BRPI0713736A2 (pt) * 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
CN101472883A (zh) * 2006-06-20 2009-07-01 弗·哈夫曼-拉罗切有限公司 芳基磺酰氨基四氢萘衍生物以及其应用
MX2010004622A (es) 2007-11-06 2010-05-20 Edison Pharmaceuticals Inc Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales.
WO2010030607A1 (en) 2008-09-10 2010-03-18 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
EP2750697A4 (de) 2011-09-02 2015-03-25 Medtronic Inc Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung
JP2016520621A (ja) * 2013-05-31 2016-07-14 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのカルボン酸誘導体
RU2770091C2 (ru) 2014-12-16 2022-04-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Полиморфные и аморфные формы (r)-2-гидрокси-2-метил-4-(2,4,5-триметил-3,6-диоксоциклогекса-1,4-диенил)бутанамида
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL112041C (de) * 1954-03-08
GB947885A (en) * 1961-04-12 1964-01-29 Vitamins Ltd Improvements in or relating to the preparation of chromanols
GB949715A (en) * 1961-04-12 1964-02-19 Vitamins Ltd Improvements in or relating to chromanols
US3726904A (en) * 1970-11-16 1973-04-10 Ciba Geigy Corp 2,3-dihydro-5-(2-nitro-1-alkenyl)-benzofuran-2-carboxylic acid and pharmaceutically acceptable salts
US3947473A (en) * 1972-12-22 1976-03-30 Hoffman-La Roche Inc. Antioxidant chroman compounds
US4018799A (en) * 1973-11-19 1977-04-19 Hoffmann-La Roche Inc. Antioxidant chroman compounds
US4026907A (en) * 1973-11-19 1977-05-31 Hoffmann-La Roche Inc. Antioxidant chroman compounds
US4003919A (en) * 1973-11-19 1977-01-18 Hoffmann-La Roche Inc. Antioxidant chroman compounds
US4100294A (en) * 1976-12-06 1978-07-11 Merck & Co., Inc. 5-(Hydroxy (substituted) methyl)-2,3-dihydrobenzo furan-2-carboxylic acid and its derivatives
US4127608A (en) * 1977-05-17 1978-11-28 Hoffmann-La Roche Inc. Synthesis of Vitamin E
DE2861183D1 (en) * 1978-01-30 1981-12-24 Hoffmann La Roche Process for the preparation of chromane derivatives
US4237130A (en) * 1979-06-21 1980-12-02 Merck & Co., Inc. 2,3-Dihydro-6,7-disubstituted-5-(substituted sulfonyl)benzofuran-2-carboxylic acids
DE3010504A1 (de) * 1980-03-19 1981-10-01 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von 2-hydroxyalkylchromanen
US4321270A (en) * 1981-01-29 1982-03-23 E. R. Squibb & Sons, Inc. Substituted chromans
JPS57145871A (en) * 1981-03-05 1982-09-09 Eisai Co Ltd Chromanolcarboxylic derivative
JPS6163671A (ja) * 1984-09-05 1986-04-01 Shionogi & Co Ltd ２，３−ジヒドロベンゾフラン−５−スルホンアミド誘導体および降圧利尿剤
US4728650A (en) * 1985-05-13 1988-03-01 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives and medicinal uses thereof
US4791209A (en) * 1985-05-22 1988-12-13 Chugai Seiyako Kabushiki Kaisha Furobenzisoxazole derivatives
DK36389A (da) * 1988-02-05 1989-08-06 Eastman Kodak Co Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion
JPH01303467A (ja) * 1988-05-31 1989-12-07 Mita Ind Co Ltd 画像形成装置の中間調制御装置
EP0369082A1 (de) * 1988-11-14 1990-05-23 Merrell Dow Pharmaceuticals Inc. Herzschutz-Tocopherolanaloge
IT1231341B (it) * 1989-08-18 1991-11-28 Foscama Biomed Chim Farma 2,3 diidro 5 ossi 4,6,7 trimetilbenzofurani 2 (rs) sostituiti, utili come farmaci antiossidanti con proprieta' mucoregolatrici e antiischemiche.
JP3029840B2 (ja) * 1990-01-18 2000-04-10 旭電化工業株式会社 光学活性なクロマン―２―エタノール誘導体の製造方法およびその中間体
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4121468A1 (de) * 1991-06-28 1993-01-14 Deutsches Primatenzentrum Gmbh Antivirale substanzen und diese enthaltende arzneimittel

Also Published As

Publication number Publication date
EP0792270A1 (de) 1997-09-03
US6150402A (en) 2000-11-21
US6083982A (en) 2000-07-04
JPH10506383A (ja) 1998-06-23
EP0792270B1 (de) 2003-05-07
AU3327795A (en) 1996-03-07
ATE239465T1 (de) 2003-05-15
WO1996005191A1 (en) 1996-02-22
JPH10510656A (ja) 1998-10-13

Similar Documents

Publication Publication Date Title
DE69530701D1 (de) Verwendung von 2,7,8-Trimethyl-2-( beta-Carboxyethyl )-6-Hydroxy-Chroman (LLU-alpha)
DE69525883D1 (de) Positiv-photoresistzusammensetzung
DE69705980D1 (de) Positiv-arbeitende fotoempfindliche Zusammensetzung
DE69510519D1 (de) Positiv-arbeitende fotoempfindliche Zusammensetzung
KR970002471A (ko) 포지티브형 포토레지스트조성물
DE68927140D1 (de) Photolackzusammensetzung
DE68910106D1 (de) Vaginalschwamm.
DE68913050D1 (de) Antithrombotische zusammensetzung.
DE69714502D1 (de) Positiv-arbeitende lichtempfindliche Zusammensetzung
DE3853694D1 (de) Photolackzusammensetzung.
DE69712253T2 (de) Positiv-arbeitende fotoempfindliche Zusammensetzung
TR26415A (tr) Yumusak sampuan terkipleri
DE3851921D1 (de) Photopolymerisierbare Zusammensetzung.
DE69123873D1 (de) Photoresistzusammensetzung
DE69503738D1 (de) Fotopolymerisierbare Zusammensetzung
IT1240773B (it) Perfezionamento composizioni pozzolaniche.
DE69626898D1 (de) Strahlungsempfindliche Zusammensetzung
KR970702904A (ko) 중합성 조성물(polymerizable compositions)
DE69502645D1 (de) Fotoempfindliche Zusammensetzung
DE69423053T2 (de) Relaismatrixendstufe
DE69501208D1 (de) Pfropfcopolymerisat enthaltende waschmittelzusammensetzung
DE69124865D1 (de) Photolackzusammensetzung
KR960003693U (ko) 남성용 팬티
KR960016196U (ko) 테이블의 지각 결착구
DK70490D0 (da) Amalgamfilter

Legal Events

Date Code Title Description
8332 No legal effect for de